← Back to Search

Cannabinoid

THC + Ketamine for Cannabis and Ketamine

Phase 1
Waitlist Available
Led By Rajiv Radhakrishnan, M.D.
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up -60, +70, +120, +240 from baseline (0) (units in minutes).
Awards & highlights

Study Summary

This trial will assess the safety of combining the drugs ketamine and THC, as well as the effects of the combination on cognition and behavior.

Eligible Conditions
  • Cannabis
  • Ketamine

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~-60, +70, +120, +240 from baseline (0) (units in minutes).
This trial's timeline: 3 weeks for screening, Varies for treatment, and -60, +70, +120, +240 from baseline (0) (units in minutes). for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
EEG Measures 1
EEG Measures 2
EEG Measures 3
+6 more
Secondary outcome measures
Cannabis Subjective Effects
Perceptual Alterations
Positive and Negative Symptoms Scale (PANSS)

Trial Design

4Treatment groups
Experimental Treatment
Group I: Placebo Delta-9-THC and Placebo KetamineExperimental Treatment2 Interventions
IV Placebo Delta-9-THC and Placebo Ketamine
Group II: Placebo Delta-9-THC and Active KetamineExperimental Treatment2 Interventions
IV Placebo Delta-9-THC and Active Ketamine
Group III: Active Delta-9-THC and Placebo KetamineExperimental Treatment2 Interventions
Active IV Delta-9-THC and Placebo Ketamine
Group IV: Active Delta-9-THC and Active KetamineExperimental Treatment2 Interventions
Active IV Delta-9-THC and Active Ketamine
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo Ketamine
2019
Completed Phase 1
~30
Active Delta-9-THC
2015
Completed Phase 1
~60
Placebo Delta-9-THC
2019
Completed Phase 1
~30
Active Ketamine
2019
Completed Phase 1
~30

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Brain & Behavior Research FoundationOTHER
61 Previous Clinical Trials
2,792 Total Patients Enrolled
Yale UniversityLead Sponsor
1,848 Previous Clinical Trials
2,737,796 Total Patients Enrolled
14 Trials studying Cannabis
802 Patients Enrolled for Cannabis
Rajiv Radhakrishnan, M.D.Principal InvestigatorYale University

Media Library

Delta-9-THC (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT04199468 — Phase 1
Cannabis Research Study Groups: Active Delta-9-THC and Active Ketamine, Active Delta-9-THC and Placebo Ketamine, Placebo Delta-9-THC and Active Ketamine, Placebo Delta-9-THC and Placebo Ketamine
Cannabis Clinical Trial 2023: Delta-9-THC Highlights & Side Effects. Trial Name: NCT04199468 — Phase 1
Delta-9-THC (Cannabinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04199468 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis
Rajiv Radhakrishnan, MD 2019. "THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04199468.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top